Belleric myrobalan

Belleric Myrobalan (Terminalia bellirica): A Comprehensive Reference

1. Identity and Botanical Classification

Nomenclature

Belleric myrobalan is correctly identified as Terminalia bellirica (Gaertn.) Roxb., a large deciduous tree in the family Combretaceae. The basionym is Myrobalanus bellirica Gaertn., later transferred to Terminalia by William Roxburgh. A widely circulated spelling variant — Terminalia bellerica — is now widespread in the scientific literature but represents a spelling error introduced by Roxburgh; the taxonomically correct name retains the double "i": T. bellirica.

Common names in English include bastard myrobalan, bedda nuts, belleric myrobalan, and bohera. In Arabic the fruit is known as beliledj (borrowed from Middle Persian Balilag); in Persian it is Balileh; in Sanskrit it is Bibhītaka or Aksha. Additional vernacular designations include Baheda and Bahera in Hindi, Behada in Marathi, and balelaa in Bangladesh.

Botanical Description and Distribution

The tree belongs to the family Combretaceae. It has thick brownish-gray bark and produces a grayish-yellow, velvety, ovoid drupe. It is a large deciduous tree native to the Indian subcontinent and Southeast Asia. It is common on the plains and lower hills in South and Southeast Asia, where it is also grown as an avenue tree. In India, Neemuch in the Malwa region of Madhya Pradesh is a major trading centre for the fruit; the fruits are widely collected in the wild in that region.

Two varieties of T. bellirica are found in India: one with nearly globular fruit about ½ to ¾ inch in diameter, and another with an ovate and much larger fruit. The tree produces a grayish-yellow, velvety, ovoid drupe, and the dried fruit rind is the component most frequently used in medicinal preparations.

Parts Used and Common Preparation Forms

The fruit is the primary part utilized, celebrated for its diverse therapeutic properties. Terminalia bellerica is available in several forms. The most common preparation is the dried fruit powder (Bibhitaki churna), which can be taken alone or as part of the Triphala formulation. Other preparations include concentrated aqueous extracts, hydroalcoholic extracts, and fruit oils. In the context of Triphala, T. bellirica is administered in various forms, including churna (fine powder), kwatha (decoction), mashi (ash), taila (oil), and gritha (cooked with clarified butter or ghee). The fruit also yields a green fixed oil, saponins, a resinous residue, and hygroscopic glycosidal compounds. The fixed oil contains esters of palmitic, stearic, oleic, and linoleic acids. Triterpenes such as belleric acid and its glucoside bellericoside have been isolated from the fruits.

2. Traditional and Historical Use

Ayurveda

Terminalia bellirica is one of the oldest medicinal herbs of India, Pakistan, Nepal, Bangladesh, Sri Lanka, and South-East Asia. Its medicinal utility has been described in different traditional medicinal systems, including Ayurveda, Unani, Siddha, and traditional Chinese medicine. Traditional practice of Ayurveda in ancient India dates back to at least the first millennium BC.

Triphala, a well-recognized polyherbal Ayurvedic medicine consisting of the fruits of Emblica officinalis (Amalaki), Terminalia bellirica (Bibhitaki), and Terminalia chebula (Haritaki), is a cornerstone of gastrointestinal and rejuvenative treatment. It is classified as a tridoshic rasayana in Ayurvedic medicine, as it promotes longevity and rejuvenation in patients of all constitutions and ages. Triphala traces back at least 2,000 years to classical Ayurvedic texts; it is mentioned in the Charaka Samhita (Vimanasthana 2.134) as "three fruits in equal parts" used for nurturing of ojas and balancing all three doshas.

In the ancient Ayurvedic textual tradition, T. bellerica fruits were ascribed the qualities of diminishing disease and bestowing longevity, intellectual powers, and strength. Traditionally, the fruit is described as having an astringent and laxative quality, often prescribed to support the throat and chest. Traditionally, T. bellerica has been used for treatment of various conditions including conjunctivitis, asthma, migraine, baldness, constipation, and weak eyesight.

Unani Medicine

T. bellirica has been used in varied traditional systems of medicine, including Ayurveda, Siddha, Unani, and traditional Chinese medicine. However, very limited human studies on T. bellirica alone have been reported, while numerous clinical studies have been conducted on its herbal formulation Triphala. In Unani material medica, the fruit is categorized among the three myrobalans (Halela siah, Balela, and Amla) and employed in compound formulations addressing respiratory, digestive, and inflammatory conditions.

A traditional Ayurvedic herbal combination is a mixture of three herbs, two of which are Terminalia species: T. bellirica (for health-harmonizing qualities), T. chebula (to normalize body balance), and Emblica officinalis (for vitamin C content). This formulation, Triphala, is used for its laxative, detoxifying, and rejuvenating effects. In traditional usage, T. bellirica has been used to treat diarrhea, scorpion stings, and cough.

Traditional Chinese and Southeast Asian Medicine

The medicinal utility of T. bellirica has been described across Ayurveda, Unani, Siddha, and traditional Chinese medicine. According to Dymock, Warden, and Hooper's Pharmacographia Indica (1890), the tree — called Bibhita and Bibhitaka ("fearless") in Sanskrit — was associated with folk beliefs in Northern India wherein the tree was said to be inhabited by demons, leading Hindus to avoid sitting in its shade.

3. Key Phytochemical Constituents

Hydrolyzable Tannins

The biological activity of Terminalia bellerica is largely attributed to its dense concentration of polyphenolic compounds, particularly hydrolyzable tannins. These compounds constitute a significant portion of the fruit pulp. Prominent examples include gallic acid and ellagic acid, which contribute substantially to astringency and antioxidant capacity. Other related tannins, such as chebulagic acid and corilagin, are also present.

Diverse bioactivities of T. bellirica have been ascribed to the presence of many bioactive phytochemicals, including glucoside, tannins, gallic acid, corilagin, ellagic acid, ethyl gallate, galloyl glucose, chebulagic acid, and arjunolic acid. Tannins such as phyllemblin, bellericannin, chebulagic acid, and phenolics including gallic acid, ellagic acid, and ethyl gallate have also been reported to be present in the fruits.

Lignans, Flavonoids, and Other Classes

The fruit contains various other classes of compounds, including lignans like termilignan, glycosides such as bellericanin, flavonoids, and saponins. Additional biologically active phytochemicals include β-sitosterol, gallo-tannic acid, 7-hydroxy-3′,4′-(methylenedioxy)flavone, luteolin, belleric acid, and chebulagic acid. Flavonoids including quercetin rutinoside and quercetin galloyl-glucoside further contribute to the phytochemical profile; beta-sitosterol has also been identified.

Volatile Terpenoids and Fixed Oils

Previous studies using GC-MS headspace analysis identified volatile terpenoids including endo-borneol, linalool, terpinene-4-ol, methoxy citronellal, pinocarveol, eucalyptol, carvone, camphor, L-fenchone, hyscylene, patchoulane, p-cumic aldehyde, and phenylbutanal. The fixed oil in the fruit contains esters of palmitic, stearic, oleic, and linoleic acids.

Sugars and Miscellaneous Constituents

The fruit pulp also contains mannitol, glucose, fructose, and rhamnose, alongside gallotannic acid and the lignans termilignan, thannilignan, and anolignan B.

4. Mechanisms of Action

Antioxidant Activity

Secondary plant metabolites, phenolic compounds, and flavonoids exhibit antioxidant activities. Investigations have shown that T. bellerica fruit pulp possesses antioxidant activity demonstrated by significant reducing power, overall antioxidant capacity, hydroxyl radical scavenging, and free radical scavenging. The high content of these antioxidant compounds allows the extracts to scavenge free radicals and mitigate oxidative stress at a cellular level.

Xanthine Oxidase Inhibition (Uric Acid Pathway)

Studies show its potential in inhibiting xanthine oxidase, an enzyme involved in uric acid production. The possible mechanism of anti-inflammatory action in inflammatory conditions like arthritis and gout could also be due to inhibition of inducible nitric oxide synthase.

Antispasmodic and Bronchodilatory Mechanisms

Research has reported the presence of a combination of anticholinergic and calcium-channel antagonist effects in T. bellerica, which provides a pharmacological basis for its medicinal use in hyperactive gut and airway disorders. Crude extract of T. bellerica fruit caused relaxation of spontaneous contractions in isolated rabbit jejunum at 0.1–3.0 mg/mL. It inhibited carbachol (1 μM)- and K⁺ (80 mM)-induced contractions in a pattern similar to dicyclomine. The extract shifted Ca²⁺ concentration-response curves to the right, similar to nifedipine and dicyclomine. These results indicate that T. bellerica fruit possesses a combination of anticholinergic and Ca²⁺ antagonist effects, which explain its folkloric use in colic, diarrhea, and asthma.

Anti-inflammatory Mechanisms

Studies have examined in vivo anti-inflammation effects of T. bellerica extract using ethyl phenylpropiolate- and arachidonic acid-induced ear edema models, a cotton pellet-induced granulation formation model, and a carrageenan-induced hind paw edema model. The polyphenolic constituents, particularly gallic acid and ellagic acid, are considered principal mediators of these anti-inflammatory effects.

Hepatoprotective Mechanisms

T. bellirica fruit extracts and its phytoconstituent ellagic acid are expected to provide protection against oxidative stress and liver damage. The in vitro antioxidant activities were measured by metal ion chelation and nitric oxide radical scavenging assays. In vivo antioxidant and hepatoprotective effects of T. bellirica fruit extracts and ellagic acid indicate potential to act as a hepatoprotectant and antioxidant in drug-induced hepatotoxicity and oxidative stress.

Anticancer Mechanisms (In Vitro and Animal Data)

A study evaluated the anti-cancer efficacies of octyl gallate and gallic acid isolated from T. bellirica in breast cancer cell lines and a DMBA-induced animal model. Western blot analysis showed significant downregulation of anti-apoptotic proteins (Bcl-2 and Bcl-xL) and upregulation of pro-apoptotic proteins (Bak and Bax) in both MCF-7 and MDA-MB-231 cell lines.

Acetylcholinesterase Inhibition

Phytoconstituents including gallic acid, ellagic acid, and phenolic acids present in the fruit of T. bellirica have been shown to inhibit acetylcholinesterase, suggesting a potential, so far only exploratory, basis for use in symptomatic management of Alzheimer's disease.

5. Scientific Evidence by Area of Use

5.1 Hyperuricemia and Gout

This is the area for which the most robust, directly attributed clinical evidence exists for T. bellirica as a stand-alone intervention.

Pilot clinical study (PMC, 2016): A total of 110 eligible subjects with hyperuricemia were enrolled and randomized to one of five treatment groups: T. chebula 500 mg twice daily, T. bellerica 250 mg twice daily, T. bellerica 500 mg twice daily, placebo twice daily, or febuxostat 40 mg once daily, for 24 weeks. Serum uric acid levels were measured at baseline and at the end of 4, 8, 12, 16, 20, and 24 weeks. All active treatment groups showed a reduction in serum uric acid levels compared to baseline and placebo. Significant reduction in mean serum uric acid levels started as early as 4 weeks following treatment compared to baseline.

Dose-response clinical study in CKD subjects (BMC Complementary Medicine, 2020): An earlier clinical study demonstrated that an aqueous extract of T. bellerica (TBE) significantly reduced uric acid levels with no serious adverse effects in hyperuricemic subjects. The objective of this follow-on study was to determine efficacy and tolerability in reducing uric acid and creatinine levels in CKD subjects. Fifty-nine subjects were randomized to three groups: febuxostat 40 mg once daily, TBE 500 mg twice daily, and TBE 1000 mg twice daily. At 24 weeks, febuxostat, T. bellerica 500 mg twice daily, and T. bellerica 1000 mg twice daily decreased mean percentage serum uric acid by 63.70 ± 4.62%, 19.84 ± 6.43%, and 33.88 ± 4.95% respectively (p ≤ 0.0001). Positive improvements were made by all groups in endothelial function and related biomarkers and high-sensitivity C-reactive protein. None of the products showed an effect on platelet aggregation. In this 24-week study, febuxostat 40 mg, T. bellerica 500 mg twice daily, and 1000 mg twice daily significantly decreased serum uric acid and creatinine levels and increased eGFR in CKD subjects; T. bellerica 500 mg twice daily and 1000 mg twice daily were one-third and more than half as effective as febuxostat at 24 weeks, respectively.

Evidence strength: Moderate. The two randomized controlled trials are positive-controlled rather than placebo-controlled for the primary endpoint, and sample sizes are small (59–110 subjects). The CKD trial was registered retrospectively with the Clinical Trials Registry of India (CTRI/2019/11/022093). Larger, independently replicated, placebo-controlled studies are needed before definitive conclusions can be drawn.

5.2 Antioxidant, Anti-inflammatory, and Metabolic Effects

A broad spectrum of in vitro and in vivo studies has suggested various biological and pharmacological effects, including antioxidant, anti-inflammatory, immunomodulatory, antimicrobial, hepatoprotective, renoprotective, antidiabetic, anti-hyperlipidemic, and anticancer activities. However, the majority of this evidence derives from cell culture and animal models. Components including gallic and ellagic acid influence glucose metabolism and improve insulin sensitivity in laboratory settings.

Evidence strength: Preliminary. In vitro and animal model data are substantial, but direct human clinical data on antioxidant and metabolic endpoints attributable specifically to T. bellirica (as opposed to Triphala) remain limited.

5.3 Respiratory System: Antispasmodic and Bronchodilatory Effects

In a clinical study, T. bellerica was found to possess antispasmodic, antiasthmatic, and antitussive effects (Trivedi et al., 1979). This is supported mechanistically by preclinical data: the present investigation was carried out to provide the pharmacological basis for the medicinal use of T. bellerica in hyperactive gastrointestinal and respiratory disorders; crude extract was studied in vitro and in vivo. Results indicate that T. bellerica fruit possesses a combination of anticholinergic and Ca²⁺ antagonist effects, which explain its folkloric use in colic, diarrhea, and asthma.

Evidence strength: Weak to preliminary for human use. The referenced 1979 clinical study precedes modern standards for clinical trials. The mechanistic in vitro and in vivo preclinical data provide plausibility, but robust modern controlled trials are absent.

5.4 Liver Protection (Hepatoprotective Activity)

A water-soluble fraction obtained from the defatted fruits of T. bellerica caused protection against CCl₄-induced liver injury in rodents (Anand et al., 1994). A study reported antioxidant, anti-inflammatory, and hepatoprotective activities of T. bellirica fruit aqueous and ethyl acetate extracts and its bioactive compound ellagic acid against diclofenac-induced toxicity. In vitro antioxidant activities were measured by ABTS and FRAP assays, while in vivo hepatoprotective potential was assessed in serum and liver tissue of rats after oral administration for 21 days. In studies, supplementation with these extracts and ellagic acid significantly reduced adverse effects on liver function markers. The hepatoprotective action of ellagic acid was comparable to silymarin, a known liver-protective agent.

Evidence strength: Preliminary (animal/in vitro only). No adequately powered human clinical trials specifically evaluating hepatoprotective endpoints for T. bellirica alone have been identified in the peer-reviewed literature.

5.5 Antimicrobial Activity

Research indicates that T. bellerica fruit has antihelminthic activity and, in preliminary antimicrobial analysis, inhibits coagulase activity of Staphylococcus aureus, while causing biochemical alterations in both S. aureus and Klebsiella pneumoniae strains. Fractional inhibitory concentration studies revealed additive interactions between some conventional antibiotics and the plant extracts. LC-MS analyses confirmed that the T. bellirica extracts contain various tannins.

Evidence strength: Preliminary (in vitro only). No clinical trials testing T. bellirica for infectious disease endpoints in humans have been identified.

5.6 Anticancer Activity

Bioactive compounds derived from Terminalia bellirica show potential for antioxidant, anti-inflammatory, antiviral, antiplatelet, antidiabetic, wound-healing, antidepressant, and anticancer properties. In hepatocellular carcinoma models, T. bellerica combined with cisplatin in low-to-medium doses in A549 cells showed synergistic and additive effects. A low-dose combination of T. bellerica and doxorubicin showed synergistic effects in HepG2 cells. All other combinations demonstrated antagonistic effects.

Evidence strength: Exclusively preclinical (in vitro and animal). No human clinical oncology trials have been identified. All anticancer evidence is mechanistic or experimental and should not be extrapolated to clinical outcomes.

5.7 Triphala Formulation — Clinical Evidence

Because T. bellirica is most widely used as part of Triphala, the clinical evidence base for Triphala is relevant context, though it cannot be attributed solely to T. bellirica.

In addition to laxative action, Triphala research has found the formula to be potentially effective for appetite stimulation, reduction of hyperacidity, antioxidant, anti-inflammatory, immunomodulating, antibacterial, antimutagenic, adaptogenic, hypoglycemic, antineoplastic, chemoprotective, and radioprotective effects, and prevention of dental caries. Triphala comprises equal proportions of Emblica officinalis (Amalaki), Terminalia bellirica (Bibhitaki), and Terminalia chebula (Haritaki), demonstrating exceptional efficacy in gastrointestinal health and rejuvenation therapy.

6. Body Systems and Health Areas Associated with T. bellirica

• Renal and metabolic: Hyperuricemia management (xanthine oxidase inhibition), CKD-associated uric acid reduction, creatinine modulation, and eGFR improvement — supported by RCT evidence.
• Gastrointestinal: Traditionally, the fruit is described as having an astringent and laxative quality. Antidiarrheal, antispasmodic, and antiflatulent uses are supported by in vitro and animal mechanistic data.
• Respiratory: Antiasthmatic, antitussive, and bronchodilatory applications supported by historical clinical reference and preclinical mechanistic data.
• Hepatic: Hepatoprotection against drug-induced and chemical-induced liver injury; evidence is animal/in vitro.
• Antimicrobial: Activity against respiratory pathogens and gastrointestinal pathogens demonstrated in vitro.
• Oncological (preclinical only): Apoptosis induction and tumor growth modulation studied in cell lines and animal models.
• Neurological (exploratory): Acetylcholinesterase inhibition by polyphenolic constituents is of preliminary interest for neurodegeneration research.
• Cardiovascular/Lipid: In combination as Triphala, the formulation is used to lower cholesterol and to prevent death of heart tissue. Evidence for T. bellirica alone in this context is not well established in human trials.

7. Dosage Forms and Dosages Reported in Studies

Traditional Ayurvedic texts suggest a general dose range of 3 to 6 grams for the dried fruit or powder. Modern clinical studies have utilized aqueous extracts at doses ranging from 500 mg to 1000 mg daily.

Specific dosages documented in peer-reviewed clinical studies include:

• T. bellerica 250 mg twice daily (BID) and 500 mg BID as aqueous extracts, for 24 weeks in subjects with hyperuricemia.
• 500 mg twice daily and 1000 mg twice daily of aqueous T. bellerica extract, for 24 weeks in CKD subjects with hyperuricemia, compared against febuxostat 40 mg once daily.
• In a Triphala study, 1 capsule (350 mg) of Triphala with meals three times daily (1050 mg/day) for 2 weeks was administered to healthy volunteers.

Terminalia bellerica is generally considered well-tolerated and possibly safe when used for up to 24 weeks. The doses used in available clinical trials for the aqueous extract range from 500 mg to 2000 mg per day in divided doses. Dosages for the crude dried fruit powder in traditional use are higher (grams range) and are derived from classical Ayurvedic texts rather than controlled clinical studies.

8. Safety, Tolerability, and Notable Interactions

General Tolerability

Terminalia bellerica is generally considered well-tolerated and possibly safe when used for up to 24 weeks. However, potential side effects can occur with higher doses, including gastrointestinal upset such as diarrhea or vomiting. In clinical studies, adverse reactions similar to those seen with placebo — such as constipation, headache, abdominal discomfort, and body ache — have been described.

Pregnancy and Lactation

There is evidence that Terminalia arjuna is possibly unsafe during pregnancy; the safety of T. bellirica during pregnancy is unknown. Use of any Terminalia species during pregnancy is currently not well-supported by evidence. There is not enough reliable information about safety during breastfeeding either.

Diabetes and Blood Sugar

Terminalia may lower blood sugar levels, and dosages of diabetes medications may need to be adjusted if taken concomitantly.

Perioperative Considerations

Terminalia might decrease blood sugar levels and interfere with blood sugar control during surgery. Cessation at least 2 weeks before a scheduled surgery has been recommended on this basis.

Antiplatelet and Anticoagulant Potential

Experiments in rats administered a fruit extract of T. bellirica have demonstrated an antiplatelet and anticoagulant action similar to that of acetylsalicylic acid. The clinical relevance of this finding in humans has not been established, but it warrants caution in individuals using anticoagulant or antiplatelet medications.

Interaction with Cytotoxic Agents

In vitro studies demonstrated that T. bellirica combined with cisplatin in low-to-medium doses showed synergistic and additive effects in A549 cells, and a low-dose combination with doxorubicin showed synergistic effects in HepG2 cells; however, other combinations showed antagonistic effects. These findings are based on cell culture experiments only and their clinical significance is entirely unknown.

Evidence Gaps

Preclinical and clinical studies have suggested that T. bellirica plant and its phytoconstituents have immense potential for prevention and treatment of various diseases. Additional in vivo studies and clinical trials are warranted to realize the complete medicinal attributes of this plant. Only a very limited number of human studies on T. bellirica alone have been reported.

References

• Pingali U et al. "A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia." BMC Complementary Medicine and Therapies (2020)
• Murali YK et al. "A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia." PMC / Clinical Pharmacology (2016)
• Gupta A et al. "Terminalia bellirica (Gaertn.) Roxb. (Bahera) in health and disease: A systematic and comprehensive review." Phytomedicine (2020)
• Peterson CT et al. "Therapeutic Uses of Triphala in Ayurvedic Medicine." Journal of Alternative and Complementary Medicine (2017) — PMC5567597
• PMC. "Triphala's characteristics and potential therapeutic uses in modern health." PMC (2025)
• Gilani AH et al. "Mechanisms underlying the antispasmodic and bronchodilatory properties of Terminalia bellerica fruit." Journal of Ethnopharmacology (2008)
• Patra S et al. "Terminalia bellirica extract induces anticancer activity through modulation of apoptosis and autophagy in oral squamous cell carcinoma." Food and Chemical Toxicology (2020)
• Bhattacharyya P et al. "Aceclofenac-induced hepatotoxicity: An ameliorative effect of Terminalia bellirica fruit and ellagic acid." World Journal of Gastroenterology / PMC7701975
• Phytochemical Analysis and Antimicrobial Activity of Terminalia bellirica and Terminalia chebula Fruit Extracts Against Gastrointestinal Pathogens. PubMed (2024)
• Octyl Gallate and Gallic Acid Isolated from Terminalia bellirica in Breast Cancer. Applied Biochemistry and Biotechnology (2023)
• Kumari M, Jain S. "In vitro antioxidant and inhibitory potential of Terminalia bellerica and Emblica officinalis fruits against LDL oxidation and key enzymes linked to type 2 diabetes." Food and Chemical Toxicology (2011)
• Terminalia bellirica — Biodiversity at LUMS (botanical identity and nomenclature)
• Terminalia bellirica (Gaertn.) Roxb. (Combretaceae): a medicinal tree of India. ResearchGate (2024)
• Terminalia: Uses, Benefits & Dosage — Drugs.com Natural Products Database
• Terminalia: Health Benefits, Side Effects, Uses, Dose & Precautions — RxList
• The Science-Backed Health Benefits of Terminalia Bellerica — ScienceInsights (2025)
• Terminalia bellirica — Wikipedia (botanical and nomenclatural background)